Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Capital Expenditures (2020 - 2025)

Elicio Therapeutics filings provide 4 years of Capital Expenditures readings, the most recent being $45000.0 for Q3 2023.

  • On a quarterly basis, Capital Expenditures changed N/A to $45000.0 in Q3 2023 year-over-year; TTM through Dec 2023 was $66000.0, a 89.91% decrease, with the full-year FY2025 number at $16000.0, down 81.61% from a year prior.
  • Capital Expenditures hit $45000.0 in Q3 2023 for Elicio Therapeutics, up from $4000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $559000.0 in Q2 2022 to a low of -$342000.0 in Q4 2021.
  • Median Capital Expenditures over the past 4 years was $20000.0 (2020), compared with a mean of $56000.0.
  • The widest YoY moves for Capital Expenditures: up 2340.0% in 2021, down 8650.0% in 2021.
  • Elicio Therapeutics' Capital Expenditures stood at $4000.0 in 2020, then plummeted by 8650.0% to -$342000.0 in 2021, then soared by 127.78% to $95000.0 in 2022, then crashed by 52.63% to $45000.0 in 2023.
  • The last three reported values for Capital Expenditures were $45000.0 (Q3 2023), $4000.0 (Q2 2023), and $17000.0 (Q1 2023) per Business Quant data.